Berapa harga Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Harga Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) adalah $3.91

Apa kapitalisasi pasar Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Kapitalisasi pasar Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) adalah $524.79M

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) Dividen

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.

Tahun	Dividen (disesuaikan dengan stock split)	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Dividen (disesuaikan dengan stock split)

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Tahun	Dividen	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Dividen

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Jumlah pembayaran dividen	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Perusahaan

Jumlah pembayaran dividen

Negara